JAD's Alzheimer Funding Analyzer now includes Alzheimer's Association grants

December 19, 2016

The Journal of Alzheimer's Disease (JAD) is pleased to announce that its Alzheimer's Funding Analyzer (AFA) now includes all Alzheimer's Association (AA) grants in addition to grants from other funding bodies. AFA is a free service that is part of a suite of online features integrated into the JAD site to meet the needs of the Alzheimer disease (AD) research community.

There are currently 1,080 Alzheimer's Association grants represented on the site with an aggregated funding amount of $189.5 million and average funding amount of $175,000. Top institutions by total funding amount receiving Alzheimer's Association grants include New York University; Case Western Reserve University; Icahn School of Medicine at Mount Sinai; Columbia University Medical Center; Massachusetts General Hospital; and the University of California, San Diego.

AFA empowers the AD community to track all organizations currently funding AD research around the globe. It consolidates in-depth data on 167 funders from 54 countries including the United States, Canada, United Kingdom, European Union, Ireland, Australia, and Qatar. It is comprised of close to 22,000 Alzheimer grants representing $16.5 billion in Alzheimer-related research.

New funding information is continuously added to AFA. The top five funders are the National Institute on Aging, National Institute of Neurological Disorders and Stroke, National Institute of Mental Health (USA), Medical Research Council (UK), and European Commission.

AFA enables users to easily locate funding related to AD and analyze funding streams and trends. Further, it facilitates a better understanding of research organizations' funding portfolios and the funding patterns of specific funders, both of which are critical when developing grant applications. For example, users can conduct line-of-investigation queries (e.g., tau, ApoE4, vaccine) to look for funding trends and determine which investigators in which countries have been the most successful in obtaining funding in a specific area of AD research.

"Now expanded with inclusion of AA grants, we are very excited to provide this comprehensive listing of the funding that has made progress possible, which can be studied to understand how Alzheimer's disease research is developing," commented JAD's Editor-in-Chief George Perry, PhD, Dean and Professor of Biology, The University of Texas at San Antonio.

Working with development partner ÜberResearch, a solutions and services company focused on the needs of science funders, AFA includes all funding related to AD drawn from ÜberResearch's extensive grant database of more than $1.1 trillion of funded research, representing more than 3.4 million projects from 258 different funders like the National Institutes of Health and the National Science Foundation in the U.S. and the Wellcome Trust and U.K. Research Councils in the U.K.

"ÜberResearch is honored to collaborate with our friends at JAD and the Alzheimer's research community. We hope to provide more information on global funding, support better research decisions, and expedite the development of treatments and the search for a cure," said Christian Herzog, CEO of ÜberResearch.

Free registration on JAD not only enbles users to access AFA, but also to use other features on the site.

IOS Press

Related Alzheimer Disease Articles from Brightsurf:

Potential link for Alzheimer's disease and common brain disease that mimics its symptoms
A new study by investigators from Brigham and Women's Hospital uncovered a group of closely related genes that may capture molecular links between Alzheimer's disease and Limbic-predominant Age-related TDP-43 Encephalopathy, or LATE, a recently recognized common brain disorder that can mimic Alzheimer's symptoms.

Uncovering Alzheimer's disease
Characterized by a buildup of amyloid plaques in the brain, Alzheimer's is an irreversible disease that leads to memory loss and a decrease in cognitive function.

Viewpoint: Could disease pathogens be the dark matter behind Alzheimer's disease?
In a lively discussion appearing in the Viewpoint section of the journal Nature Reviews Neurology, Ben Readhead, a researcher in the ASU-Banner Neurodegenerative Disease Research Center at the Biodesign Institute joins several distinguished colleagues to discuss the idea that bacteria, viruses or other infectious pathogens may play a role in Alzheimer's disease.

Coordination chemistry and Alzheimer's disease
It has become evident recently that the interactions between copper and amyloid-╬▓ neurotoxically impact the brain of patients with Alzheimer's disease.

How Alzheimer's disease spreads through the brain
Tau can quickly spread between neurons but is not immediately harmful, according to research in mouse neurons published in JNeurosci.

A protective factor against Alzheimer's disease?
Researchers at the German Center for Neurodegenerative Diseases (DZNE) and the Institute for Stroke and Dementia Research (ISD) at the University Hospital of the Ludwig-Maximilians-Universit├Ąt (LMU) in Munich have found that a protein called TREM2 could positively influence the course of Alzheimer's disease.

An alternate theory for what causes Alzheimer's disease
Alzheimer's disease, the most common cause of dementia among the elderly, is characterized by plaques and tangles in the brain, with most efforts at finding a cure focused on these abnormal structures.

Alzheimer's: How does the brain change over the course of the disease?
What changes in the brain are caused by Alzheimer's disease?

Possible pathway to new therapy for Alzheimer's disease
Researchers have uncovered an enzyme and a biochemical pathway they believe may lead to the identification of drugs that could inhibit the production of beta-amyloid protein, the toxic initiator of Alzheimer's disease (AD).

Promising novel treatment against Alzheimer disease
New research conducted at the Lady Davis Institute (LDI) at the Jewish General Hospital reveals that a novel drug reverses memory deficits and stops Alzheimer disease pathology (AD) in an animal model.

Read More: Alzheimer Disease News and Alzheimer Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.